Two months on Min 2.5 and Dut 0.5. Shedding phase is brutal
    Update 11/21/2024

    From the encyclopedia
    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    💊 Minoxidil (oral) 2.5mg daily 2 months
    💊 Dutasteride (oral) 0.5mg daily 2 months
    the tone is hopeful.

    Other terms

    The conversation discusses the challenges and experiences of using minoxidil, finasteride, and dutasteride for hair loss, focusing on the shedding phase and its impact on hair appearance. Users share their personal experiences, side effects, and hopes for improvement, with some considering or having undergone hair transplants.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results

      research Androgens and hair loss

      52 citations , June 2009 in “Current Opinion in Endocrinology, Diabetes and Obesity”
      This review discusses the pathogenesis and treatment of androgenetic alopecia, highlighting genome associations and newer topical formulations, but reports no new clinical results.

      research Hair loss: a clinical update

      November 2019 in “Journal of Aesthetic Nursing”
      This article reviews the classifications and characteristics of androgenic alopecia and provides no new clinical results; it emphasizes the importance for aestheticians to understand current treatment evidence.

      research Androgenetic Alopecia

      1 citations , July 2018 in “Elsevier eBooks”
      This review covers androgenetic alopecia's epidemiology, pathogenesis, current management options, and research trends, concluding that no definitive cure exists despite extensive interest and ongoing genetic research efforts.

      research Safety concerns when using novel medications to treat alopecia

      23 citations , October 2018 in “Expert Opinion on Drug Safety”
      This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.